

Provisional Scientific Programme
Current to date: 30 January 2018

Pre-Congress Symposium

Room, Tuesday 22 May 2018		
CONTINUING EDUCATION IN CLINICAL TOXICOLOGY		
Chemical and Biological Weapons (CBRN) – an update for the Clinical Toxicologist		
Time	Title	Lecturer
Session chair: to be advised		
09:00 - 09:30	Acute Radiation Syndrome: A role for toxicologists?	Stephen Borron , Texas Tech University Health Sciences Center, El Paso, USA
09:30 - 10:00	Ricin, a plant toxin of special interest	Brigitte Dorner , Robert Koch Institute, Berlin, Germany
10:00 - 10:30	Botulism: the poison of the poison - a real risk?	Davide Lonati , Poison Control Centre and National Toxicology Information Centre - Toxicology Unit IRCCS Maugeri Hospital and University of Pavia, Italy
<p><i>At the end of this session the audience should be able to:</i></p> <ul style="list-style-type: none"> • describe the role of serial absolute lymphocyte counts in assessing whole body radiation dosages • explain the hallmarks of ricin toxin including its structure and function as well as its role as potential biothreat agent and to highlight pros and cons of different detection methods • explain the potential use of botulism toxin in as a potential biothreat agent and describe the clinical manifestations and treatment 		
10:30 - 11:00	Coffee	
Session chair: to be advised		
11:00 - 11:30	Mobile lab support for Ebola diagnostics - challenges, solutions and lessons learned	Roman Wölfel , Bundeswehr Medical Academy, Munich, Germany
11:30 - 12:00	From Diagnosis to Treatment of Clostridial Toxins	Panagiotis Papatheodorou , Institute of Pharmacology and Toxicology, University of Ulm Medical Center, Germany
12:00 - 12:30	Verification through Analytical Chemistry – Proving exposure to chemical warfare agents by the OPCW	Marc-Michael Blum , Organisation for the Prohibition of Chemical Weapons, Rijswijk, The Netherlands
<p><i>At the end of this session the audience should be able to:</i></p> <ul style="list-style-type: none"> • explain the principles of the mobile lab support in the Ebola outbreak 2013-15 and describe the most important lessons-learned • explain possible diagnosis and treatment options for clostridial toxins posing a potential public health threat • understand the use of biomedical sample analysis in the OPCW verification mechanism to confirm exposure to chemical warfare agents and other toxic chemicals 		
12:30 – 13:30	Lunch	

Session chair: to be advised		
13:30 - 14:00	Triage, patient decontamination, and early diagnostics after chemical warfare attacks	Dirk Steinritz , Bundeswehr Institute of Pharmacology and Toxicology, Munich, Germany
14:00 – 14:30	Therapeutic challenges in mass exposure to toxic industrial chemicals)	Peter de Paepe , Ghent University Hospital, Belgium
14:30 – 15:00	Public health aspects of chemical weapon preparedness and response: some lessons from the field	Catherine Smallwood , World Health Organization, Geneva, Switzerland
<p><i>At the end of this session the audience should be able to:</i></p> <ul style="list-style-type: none"> • <i>explain the medical challenges that occur after chemical attacks and how to cope with these issues</i> • <i>discuss the therapeutic challenges in mass exposure to toxic industrial chemicals</i> • <i>describe some of the public health, medical and other challenges that WHO has faced in recent emergencies involving toxic chemical hazards</i> 		
15:00 – 15:30	Coffee	
Session chair: to be advised		
15:30 – 16:00	Nerve Agents - Blister Agents: different challenges need different approaches	Horst Thiermann , Bundeswehr Institute of Pharmacology and Toxicology, Munich, Germany
16:00 – 16:30	Risk to and protection of hospital personnel during decontamination/treatment in the hospital	Marianne Leenders , National Poisons Information Center/ University Medical Center Utrecht, The Netherlands
16:30 – 17:00	Medical treatment through a barrier – challenges when protection is needed	Fridtjof Heyerdahl , Oslo University Hospital, Norway
<p><i>At the end of this session the audience should be able to:</i></p> <ul style="list-style-type: none"> • <i>recognise these agents as extremely toxic compounds requiring immediate protection of personnel and facilities as well as rapid decontamination of victims, and that therapy of nerve agent poisoning is aimed at antagonizing acute life-threatening effects whereas therapy of blistering agents is aimed at amelioration of pathophysiological damage to facilitate wound healing</i> • <i>recognize the risks presented to them when treating possibly contaminated patients and know how to protect themselves</i> • <i>describe different scenarios where protective equipment is needed, and challenges with developing new protective equipment</i> 		

Main Congress

Platinum Room, Wednesday 23 May 2018 (morning)		
Plenary lecture followed by New Psychoactive Substances Symposium		
Time	Title	Lecturer
Session chair: to be advised		
08:55 – 09:00	Welcome and opening	Bruno Mégarbane President EAPCCT
09:00 – 09:45	How clinical toxicologists and poisons centres contribute to addressing NPS in Europe <i>At the end of this lecture the audience should be able to understand the European Early Warning System and how Clinical Toxicologists and Poisons Centres can contribute to addressing NPS in Europe</i>	Alexis Goosdeel , European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal
09:50 – 10:05	PSYCHOACTIVE SYNTHETIC CATHINONES ELICIT MITOCHONDRIAL MYOTOXICITY BY DIFFERENT MECHANISMS (abstract no. 1)	Xun Zhou , University Hospital Basel, Switzerland
10:05 – 10:10	THE DISSOCIATIVE NEW PSYCHOACTIVE SUBSTANCES DIPHENIDINE AND METHOXPHENIDINE INTERACT WITH MONOAMINERGIC TRANSPORTERS AND RECEPTORS (abstract no. 2)	Dino Luethi , University Hospital and University of Basel, Switzerland
10:10 – 10:25	CHANGES WITH TIME IN ANALYTICALLY CONFIRMED EXPOSURE TO NOVEL PSYCHOACTIVE SUBSTANCES (NPS) IN PATIENTS WITH SEVERE CLINICAL TOXICITY IN THE UK (abstract no. 3)	Simon Thomas , Newcastle University, Newcastle-upon-Tyne, UK
10:25 – 10:30	UNDER-ESTIMATION OF NEW PSYCHOACTIVE SUBSTANCE USE IN PATIENTS PRESENTING WITH ACUTE RECREATIONAL DRUG TOXICITY TO THE EMERGENCY DEPARTMENT (abstract no. 4)	David Wood , Guys and St Thomas' NHS Foundation Trust, King's College London, UK
10:30 – 11:10	Coffee and authors with posters	
Session chair: to be advised		
11:10 – 11:25	FOUR-YEAR SURVEILLANCE TRENDS OF NEW PSYCHOACTIVE SUBSTANCES IN LONDON, UK USING POOLED URINE ANALYSIS (abstract no. 5)	John Archer , Guy's and St Thomas' NHS Foundation Trust, London, UK
11:25 – 11:30	AN INCREASING NUMBER OF CASES INVOLVING DESIGNER BENZODIAZEPINE EXPOSURES REPORTED TO THE DUTCH POISONS INFORMATION CENTER (abstract no. 6)	Antoinette Van Riel , University Medical Center Utrecht, The Netherlands
11:30 – 11:45	CLINICAL CHARACTERISTICS OF NEW DESIGNER BENZODIAZEPINES: INTOXICATION CASES FROM THE SWEDISH STRIDA PROJECT (abstract no. 7)	Matilda Bäckberg , The Public Health Agency of Sweden, Stockholm, Sweden
11:45 – 11:50	SYNTHETIC CANNABINOID RECEPTOR AGONIST (SCRA) AVAILABILITY ON DARKNET DRUG MARKETS: CHANGES DURING 2016-2017 (abstract no. 8)	Paul Dargan , Guys and St Thomas' NHS Foundation Trust, King's College London, UK

11:50 – 12:05	5F-MDMB-PINACA ON THE STREETS: CASE SERIES OF 17 POISONINGS (abstract no. 9)	Csaba Pap , Péterfy Hospital, Budapest, Hungary
12:05 – 12:20	ACUTE SYNTHETIC CANNABINOID RECEPTOR AGONIST (SCRA) TOXICITY: A CASE SERIES OF 442 PATIENTS PRESENTING TO A REGIONAL POISONS TREATMENT CENTRE (abstract no. 10)	Konstantin Brusin , Kaplan Medical Centre, Rehovot, Israel
12:20 – 12:30	General Discussion	
12:30 – 13:30	Lunch	
13:30 – 14:00	Authors with Posters and Poster Round	

Arizona & Colorado Room, Wednesday 23 May 2018 (morning)		
Novel Oral Anticoagulants Mini-Symposium		
Time	Title	Lecturer
Session chair: to be advised		
09:50 – 10:10	An update on the mechanisms of action and patterns of toxicity associated with NOACs	Carlo Locatelli , ICS Maugeri Pavia, Italy
10:10 – 10:30	Management of NOAC toxicity and new antidotes	Rama Rao , Weill Cornell Medical College, New York, USA
<p><i>At the end of this session the audience should be able to:</i></p> <ul style="list-style-type: none"> • describe the toxic mechanisms and effects of NOACs • discuss how to limit or reverse life-threatening hemorrhage in patients taking novel oral anticoagulants therapeutically or in overdose 		
10:30 – 11:10	Coffee and Authors with Posters	
APAMT Symposium on Occupational Toxicology		
Session chair: to be advised		
11:10 – 11:30	Patients with chemical exposure presenting to Bangkok Hospital in an industrial area in Thailand	Thanjira Jiranantakan , Faculty of Medicine Siriraj Hospital, Mahidol University Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
11:30 – 11:50	Occupational Lead Poisoning as a Lesson to be Learnt from Thailand	Satariya Trakulrichai , Ramathibodi Hospital, Bangkok, Thailand
11:50 – 12:10	How should we handle tetramethylammonium hydroxide (TMAH) exposure more appropriately?	Jou-Fang Deng , Taipei Veterans General Hospital, Taiwan
12:10 – 12:30	Experience in diagnosis and treatment of patients exposed to dimethyl sulfate	Xuetao Zhang , Shanghai Institute of Occupational Disease for Chemical Industry, China
<p><i>At the end of this session the audience should be able to:</i></p> <ul style="list-style-type: none"> • describe circumstances, responses, management, final outcomes and recommendations of chemically-exposed patients, especially in the context of occupational exposure in Thailand • describe occupational lead exposure in Thailand including clinical aspects and management of cottage-industry workers with high blood lead concentrations • appreciate that on-site decontamination with appropriate antidote administration are critical following exposure to tetramethylammonium hydroxide (TMAH) • describe the clinical manifestations and management of patients with acute dimethyl sulfate poisoning 		
12:30 – 13:30	Lunch	
13:30 – 14:00	Authors with Posters and Poster Round	

Platinum Room, Wednesday 23 May 2018 (afternoon)		
Poison Centre Data Collection Symposium		
Time	Title	Lecturer
Session chair: to be advised		
14: 00 – 14:20	European Poisons Centres data collection to support curative and preventative measures against poisoning - Introduction	Herbert Desel , German Federal Institute for Risk Assessment, Berlin, Germany
14:20 – 14:40	Benefits of harmonisation of product notification to Poisons Centers	Ronald de Groot , Dutch National Poisons Information Center, Utrecht, The Netherlands
14:40 – 15:00	The importance of poison centre information for international activities in assessing risks to public health	Raquel Duarte Davidson , Public Health England, Newbury, UK
<p><i>At the end of this session the audience should be able to:</i></p> <ul style="list-style-type: none"> • <i>describe the advantages and problems of harmonised poisons centres case data collection in Europe</i> • <i>describe the benefits of harmonisation of product notification to Poisons Centers in the context of future case data collection</i> • <i>understand the importance of poison centre information for international initiatives on the notification of risks to public health and how this data can be used to underpin changes to legislation</i> 		
15:00 – 15:45	Coffee and Authors with Posters	
Session chair: to be advised		
15:45 – 16:00	RESULTS FROM THE EU LIQUICAPS STUDY: A COMPARISON BETWEEN CASES EXPOSED TO LIQUID LAUNDRY DETERGENT AND AUTOMATIC DISHWASHING CAPSULES (abstract no. 11)	Laura Settimi , Italian National Institute of Health, Rome, Italy
16:00 – 16:20	Use of Poison Center data for Public Health Surveillance	Jay Schauben , Florida Poison Information Center, Jacksonville, USA
16:20 – 16:40	European poison centre data collection: where are we now and where do we want to go?	Hugo Kupferschmidt , Tox Info Suisse, Zurich, Switzerland
16:40 – 17:00	Round Table Discussion	
<p><i>At the end of this session the audience should be able to:</i></p> <ul style="list-style-type: none"> • <i>describe the methodology and list the mechanisms for use of poison center data in providing public health surveillance and mitigation of public health threats in the United States</i> • <i>understand how we can get to an European Poisoning Data System, what the scenarios, stakeholders, and requirements are, and what problems could be expected, and how it could be financed</i> 		

Arizona & Colorado Room, Wednesday 23 May 2018 (afternoon)		
Short Oral Presentations		
Time	Title	Lecturer
Session chair: to be advised		
14:00 – 14:05	FAVORABLE ACUTE TOXICITY PROFILE OF NOSCAPINE IN CHILDREN (abstract no. 12)	Colette Degrandi , National Poisons Centre, Tox Info Suisse, Zurich, Switzerland
14:05 – 14:10	TOXICOVIGILANCE THROUGH SOCIAL MEDIA: QUANTIFYING ABUSE-INDICATING INFORMATION IN TWITTER DATA (abstract no. 13)	Jeanmarie Perrone , University of Pennsylvania, Philadelphia, USA
14:10 – 14:15	SEVERE TO LETHAL METHANOL POISONING AFTER COMMERCIALY AVAILABLE DENATURED ETHANOL “PINK ALCOHOL” ABUSE (abstract no. 14)	Davide Lonati , Pavia Poison Control Centre - National Toxicology Information Centre - Clinical and Experimental Lab, Toxicology Unit, Maugeri Clinical and Scientific Institutes IRCCS and University of Pavia, Italy
14:15 – 14:20	RELATIVE RISK OF COMBINING BENZODIAZEPINE WITH OPIOIDS BASED ON NATIONAL POISON DATA SYSTEM (NPDS) EXPOSURE OUTCOME DATA (abstract no. 15)	Daniel Spyker , Oregon Health & Science University, Portland, USA
14:20 – 14:25	MORBIDITY AND FOLLOW-UP AFTER ACUTE POISONING BY SUBSTANCES OF ABUSE (abstract no. 16)	Odd Martin Valleresnes , University of Oslo, Norway
14:25 – 14:30	IMPACT OF THE UK PSYCHOACTIVE SUBSTANCES ACT 2016 ON EMERGENCY DEPARTMENT PRESENTATIONS RELATED TO SCRAS, CATHINONES AND OTHER NEW PSYCHOACTIVE SUBSTANCES (abstract no. 17)	Nicholas Webb , Guy’s and St Thomas’ NHS Foundation Trust, London, UK
14:30 – 14:35	INVESTIGATION OF THE PHARMACODYNAMIC INTERACTION INVOLVED IN THE RESPIRATORY DEPRESSION ATTRIBUTED TO DIAZEPAM/BUPRENORPHINE COMBINATION (abstract no. 18)	Dominique Vodovar , Lariboisière Hospital, Paris-Diderot University, INSERM UMR51144, Paris, France
14:35 – 14:40	INVESTIGATION OF BACLOFEN-INDUCED NEURORESPIRATORY TOXICITY: CHARACTERIZATION OF TOLERANCE DEVELOPMENT AND WITHDRAWAL SYNDROME (abstract no. 19)	Bruno Mégarbane , Lariboisière Hospital, Paris-Diderot University, INSERM UMR51144, Paris, France
14:40 – 14:45	THE DEVELOPMENT OF ANALYTICAL TECHNIQUES FOR THE CARDIAC GLYCOSIDES IN YELLOW OLEANDER (CASCABELA THEVETIA) (abstract no. 20)	Paul Dargan , Guy’s and St Thomas’ NHS Foundation Trust, King’s College London, UK
14:45 – 14:50	SERUM N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE (NT-PROBNP), NOT TROPONIN I, AT PRESENTATION PREDICTS LONG-TERM NEUROLOGIC OUTCOME IN ACUTE CHARCOAL-BURNING CARBON MONOXIDE INTOXICATION (abstract no. 21)	Byeong Jo Chun , Chonnam National University Medical School, Gwangju, South Korea
14:50 – 14:55	EARLY PROGNOSTIC FACTORS IN COLCHICINE INTOXICATION (abstract no. 22)	Carlo Locatelli , Pavia Poison Control Centre, Maugeri Clinical and Scientific Institutes IRCCS and University of Pavia, Italy

14:55 – 15:00	ILLEGAL DRUG USE IN PRISON: RESULTS OF URINARY DRUG SCREENING IN PATIENTS HOSPITALIZED IN A FRENCH INTER-REGIONAL SECURE HOSPITAL UNIT (UHSI) (abstract no. 23)	Régis Bédry , Bordeaux University Hospital, France
15:00 – 15:45	Coffee and Authors with Posters	

Arizona & Colorado Room, Wednesday 23 May 2018 (afternoon)		
Oral Platform Presentations		
Time	Title	Lecturer
Session chair: to be advised		
15:45 – 16:00	CORRELATION BETWEEN CARDIAC SYMPTOMATOLOGY, TROPONIN AND ECHOCARDIOGRAM IN CARBON MONOXIDE POISONING: PRELIMINARY DATA IN A PROSPECTIVE STUDY (abstract no. 24)	Davide Lonati , Pavia Poison Control Centre, Maugeri Clinical and Scientific Institutes IRCCS and University of Pavia, Italy
16:00 – 16:15	WHAT IS THE BEST ANTIDOTE TO REVERSE TRAMADOL-INDUCED NEURO-RESPIRATORY TOXICITY IN OVERDOSE? AN EXPERIMENTAL INVESTIGATION IN THE RAT (abstract no. 25)	Bruno Mégarbane , Lariboisière Hospital, Paris-Diderot University, INSERM UMRS1144, Paris, France
16:15 – 16:30	EFFECTS OF LIPID EMULSION ON THE PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF METOPROLOL: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSS-OVER STUDY (abstract no. 26)	Kasper Petersen , Bispebjerg and Frederiksberg University Hospital, Copenhagen, Denmark
16:30 – 16:45	INTENTIONAL ACUTE VALPROATE OVERDOSE: THE ROLE OF GASTROSCOPY FOR DECONTAMINATION OF THE GASTROINTESTINAL TRACT (abstract no. 27)	Carlo Locatelli , Pavia Poison Control Centre, Maugeri Clinical and Scientific Institutes IRCCS and University of Pavia, Italy
16:45 – 17:00	DRUG-SPECIFIC RISK OF SEVERE QT PROLONGATION FOLLOWING ACUTE DRUG OVERDOSE (abstract no. 28)	Alex Manini , Icahn School of Medicine at Mount Sinai, New York, USA

Platinum Room, Thursday 24 May 2018 (morning)		
Louis Roche lecture followed by Guidelines and Systematic Reviews Symposium (<i>plenary session</i>)		
Time	Title	Lecturer
Session chair: to be advised		
09: 00 – 09:15	Introduction and presentation of the Louise Roche Lecturer	Bruno Mégarbane President EAPCCT
09:15 – 10:00	Never ending series of surprises by 2,3,7,8-tetrachlorodibenzo-p-dioxin (2,3,7,8-TCDD)	Daniela Pelclová , General University Hospital, Charles University, Prague, Czech Republic
10:00 – 10:20	Is there a method to our madness? Methodology for systematic reviews in clinical toxicology	Sophie Gosselin , Centre antipoison du Québec, Hôpital Charles Lemoyne, Montréal, Canada
10:20 – 10:40	Shedding light on activated charcoal: Presentation by AC guideline development group	Robert Hoffman , NYU School of Medicine, New York, USA and Lotte Hoegberg , The Danish Poisons Information Centre, Bispebjerg University Hospital, Copenhagen, Denmark
<p><i>At the end of this session the audience should be able to:</i></p> <ul style="list-style-type: none"> • <i>analyse the different challenges encountered when collecting evidence to produce practice recommendations</i> • <i>understand the methods and status of the collaborative guideline on the use of activated charcoal in poisoned patients</i> 		
10:40 – 11:20	Coffee and Authors with Posters	
Session chair: to be advised		
11:20 – 11:40	To make a long story short: Presentation by QT guideline development group	Darren Roberts , NSW Poisons Information Centre, Sydney, Australia and Rittirak Othong , Faculty of Medicine Vajira Hospital, Navamindradhiraj University
11:40 – 12:30	<p><u>Pro-Con Debate:</u> Predicting Torsade - QT nomogram or fancy formulae? PRO: The nomogram is the only way</p> <p>CON: No nomogram, use the formulae</p>	Ingrid Berling , Hunter New England Local Health District, Newcastle, Australia Robert Hoffman , NYU School of Medicine, New York, USA
<p><i>At the end of this session the audience should be able to:</i></p> <ul style="list-style-type: none"> • <i>discuss challenges in conducting the QT systematic review by a group of multinational members and current updates and outline methods for maximising the clinical relevance of guidelines</i> • <i>understand the usefulness and limitations of the QT nomogram</i> • <i>describe the multiple methods for correcting the QT interval and their relative performance at predicting acute cardiovascular events in poisoned patients</i> 		

38th Congress of the EAPCCT
Bucharest, 22 – 25 May 2018

12:30 – 13:30	Lunch	
13:30 – 14:00	Authors with Posters and Poster Round	

Platinum Room, Thursday 24 May 2018 (afternoon)		
Drug-Induced Organ Failure Symposium		
Time	Title	Lecturer
Session chair: to be advised		
14:00 – 14:20	Are Berlin ARDS definition and risk factors helpful to classify and manage drug-induced respiratory failure?	Dylan de Lange , University Medical Center, Utrecht, The Netherlands
14:20 – 14:40	Is there a place for non-invasive mechanical ventilation and high-flow nasal canula to treat drug-induced respiratory failure?	Raido Paasma , Foundation Pärnu Hospital, Estonia
14:40 – 15:00	Drug-induced acute renal failure: which international classification should we use?	Dominique Vodovar , Lariboisière Hospital, Paris-Diderot University, INSERM UMRS1144, Paris, France
<p><i>At the end of this session the audience should be able to:</i></p> <ul style="list-style-type: none"> • <i>identify different levels of severity of pulmonary injury and its potential treatment options</i> • <i>describe when it is possible to use non-invasive mechanical ventilation or high-flow nasal canula to treat drug-induced respiratory failure</i> • <i>understand how to use the various international classifications to describe drug-induced renal failure and report its mechanisms and prognosis</i> 		
15:00 – 15:40	Coffee and Authors with Posters	
Session chair: to be advised		
15:40 – 15:45	BACK FROM IRREVERSIBILITY AFTER DRUG-INDUCED CARDIOVASCULAR TOXICITY TREATED WITH MASSIVE CATECHOLAMINE DOSES (abstract no. 115)	Bruno Mégarbane , Lariboisière Hospital, Paris-Diderot University, INSERM UMRS1144, Paris, France
15:45 – 16:05	The role of classic and more recent vasopressors and inotropic drugs in the treatment of drug-related cardiovascular failure	Florian Eyer , Klinikum rechts der Isar - Technical University of Munich, Germany
16:05 – 16:25	Drug-induced liver failure: new options in extracorporeal liver support techniques and liver transplantation	Julia Wendon , Kings College Hospital Foundation Trust, London, UK
16:25 – 16:45	Brain Death and the Toxicology Patient	Laura Tormoehlen , Indiana University and Indiana University Health Physicians, USA
<p><i>At the end of this session the audience should be able to:</i></p> <ul style="list-style-type: none"> • <i>describe different types of toxin-induced cardiovascular failure, list different inotropes and vasopressors and understand why these agents should be tailored to the underlying pathophysiology of shock</i> • <i>understand the differences between acute and acute-on-chronic liver failure, the evidence for extracorporeal liver support and how to identify patients who will benefit from transplantation</i> • <i>describe the challenges and potential pitfalls of declaring brain death in the toxicology patient</i> 		
17:15 – 18:30	EAPCCT General Assembly	

Arizona & Colorado Room, Thursday 24 May 2018 (afternoon)		
Oral Platform Presentations: Paracetamol Poisoning		
Time	Title	Lecturer
Session chair: to be advised		
14:00 – 14:15	FINGER PRICK CAPILLARY MICROR-122 IS A BIOMARKER OF PARACETAMOL HEPATOTOXICITY (abstract no. 116)	Marco Cirronis , Department of Neuroscience, Psychiatry, Drug Area and Child Health (NEUROFARBA) Section of Pharmacology and Toxicology, University of Florence, Italy
14:15 – 14:30	A NATIONWIDE DANISH STUDY OF THE IMPACT OF A NEW 2-BAG N-ACETYLCYSTEINE DOSING REGIMEN ON PARACETAMOL OVERDOSE MORBIDITY AND MORTALITY (abstract no. 117)	Tonny Petersen , Bispebjerg Hospital, Copenhagen, Denmark
14:30 – 14:45	THE PREDICTIVE VALUE OF OPIOID CO-INGESTION FOR ACETAMINOPHEN-INDUCED HEPATOTOXICITY (abstract no. 118)	Stephanie Hernandez , Icahn School of Medicine at Mount Sinai, New York, USA
14:45 – 15:00	ACETAMINOPHEN REPEATED SUPRATHERAPEUTIC-DOSE TOXICITY AMONG CHILDREN UNDER FIVE YEARS OLD: EFFICACY OF N-ACETYLCYSTEINE IN MONROVIA, LIBERIA (abstract no. 119)	Mohamad K Haidar , Epicentre, Universite Paris Descartes, Paris, France
15:00 – 15:40	Coffee and Authors with Posters	
Oral Platform and Short Oral Presentations		
Session chair: to be advised		
15:40 – 15:55	FISHKEEPING: A HIGH RISK SPORTS ACTIVITY? THE UNDERESTIMATED THREAT OF ZOANTHIDS (abstract no. 120)	Martin Ebbecke , University Medical Center, Göttingen, Germany
15:55 – 16:00	HYPERBARIC OXYGEN EFFECTIVELY REDUCES HARMFUL EFFECTS OF CARBON MONOXIDE IN MIXED BUT NOT IN NEURONAL CELL CULTURES (abstract no. 121)	Miran Brvar , University Medical Centre Ljubljana, Slovenia
16:00 – 16:05	INVESTIGATION OF PARACETAMOL METABOLITES TO COMPARE EFFICACY OF ACETYLCYSTEINE REGIMENS IN PARACETAMOL OVERDOSE (abstract no. 122)	Anselm Wong , Monash and Austin Health and Department of Medicine, School of Clinical Sciences, Monash University, Victoria, Australia
16:05 – 16:10	BLOOD LACTATE PROGNOSTIC IMPLICATIONS IN ACETAMINOPHEN SUPRATHERAPEUTIC-DOSE TOXICITY AMONG LOW WEIGHT CHILDREN (abstract no. 123)	Mohamad Haidar , Epicentre, Universite Paris Descartes, Paris, France
16:10 – 16:15	THE ROLE OF OXIDATIVE STRESS IN ACUTE METHANOL INTOXICATION: OXIDATIVE LIPID DAMAGE AND SUBSEQUENT NEUROINFLAMMATION (abstract no. 124)	Jiri Hlusicka , Charles University, Prague, Czech Republic.
16:15 – 16:30	CHRONIC RETINAL NEURODEGENERATION FOLLOWING ACUTE METHANOL EXPOSURE: FOUR-YEAR PROSPECTIVE STUDY IN A COHORT OF 42 SURVIVORS OF METHANOL POISONING (abstract no. 125)	Sergej Zacharov , Charles University and General University Hospital, Prague, Czech Republic

16:30 – 16:45	ATTITUDES TOWARDS RESEARCH AMONG ADULT ACUTE TOXICOLOGY ADMISSIONS (abstract no. 126)	Ailsa Campbell, University of Edinburgh, UK
17:15 – 18:30	EAPCCT General Assembly (<i>Platinum Room</i>)	

Platinum Room, Friday 25 May 2018 (morning)		
Young Investigator Award (YIA)		
(plenary session)		
Time	Title	Lecturer
Session chair: to be advised		
09:00 – 09:05	Introduction	
09:05 – 09:20	CLINICAL EFFECTIVENESS OF A SHORTER 12 HOUR ACETYLCYSTEINE (SNAP) PROTOCOL IN ROUTINE CLINICAL PRACTICE (abstract no. 206)	Ruben Thanacoody , Newcastle University, Newcastle-upon-Tyne, UK
09:20 – 09:35	ACUTE KIDNEY INJURY IN AUSTRALIAN SNAKE ENVENOMING: COMMON, MULTIFACTORIAL AND SOMEWHAT AVOIDABLE (ASP-26) (abstract no. 207)	Christopher Johnston , University of Newcastle, Australia
09:35 – 09:50	ROLE OF NOREPINEPHRINE TRANSPORTER GENE VARIATIONS IN THE CARDIOSTIMULANT EFFECTS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) (abstract no. 208)	Patrick Vizeli , University Hospital of Basel, Switzerland
09:50 – 10:05	THE POTENTIAL UTILITY OF MICRORNA FOR COMPARING EFFICACY OF ACETYLCYSTEINE REGIMENS IN PARACETAMOL OVERDOSE (abstract no. 209)	Anselm Wong , Monash and Austin Health and School of Clinical Sciences, Monash University, Victoria, Australia
10:05	Judging commences	
09:50 – 10:05	Epidemiology and evolution of clinical toxicology in Romania in the last 10 years	Viorela Nitescu , Childrens Hospital Grigore Alexandrescu, Bucharest, Romania
10:20 – 10:30	Presentation to the winner of the YIA	
10:30 – 11:10	Coffee and Authors with Posters	

Platinum Room, Friday 25 May 2018 (morning)		
Inter-individual Variability Symposium		
Time	Title	Lecturer
Session chair: to be advised		
11:10 – 11:30	Inter-individual variability in poisoning: How do I manage investigation at the bedside?	Jules Desmeules , Geneva University Hospitals, Switzerland
11:30 – 12:10	The blood-brain barrier as a variability factor in brain toxicology	Xavier Declèves , University Paris Descartes, France
12:10 – 12:30	Opioid-related fatalities: can we explain the individual risk from diversion and misuse?	Bruno Mégarbane , Paris-Diderot University, Paris, France
<p><i>At the end of this session the audience should be able to:</i></p> <ul style="list-style-type: none"> • <i>explain all available tools to investigate the inter-individual variability of toxicity features and time-course in the poisoned patient</i> • <i>be aware of new insights into transporters for psychoactive compounds in the blood-brain barrier as variability factors in brain toxicity</i> • <i>explain the reasons for the major threat presented by opioid toxicity</i> 		
12:30 – 13:30	Lunch	
13:30 – 14:00	Authors with Posters and Poster Round	

Arizona & Colorado Room, Friday 25 May 2018 (morning)		
Best paper session		
Time	Title	Lecturer
Session chair: to be advised		
An international panel have each been asked to select a clinical toxicology paper published in 2017 that they consider to be among the best. The aim is to highlight papers that have changed or challenged clinical practice, taught something new or unexpected, improved understanding of toxicological mechanisms, or inspired the panellists. The speakers will defend their choice in a brief 10 minute presentation followed by discussion.		
11:10 – 11:30	Paper 1 (title to follow)	Betty Chan , Prince of Wales Hospital and Community Health Services, Sydney, Australia
11:30 – 11:50	Paper 2 (title to follow)	Rana Biary , New York University School of Medicine, USA
11:50 – 12:10	Paper 3 (title to follow)	Irma de Vries , Dutch Poisons Information Center, University Medical Center Utrecht, The Netherlands
12:10 – 12:30	Paper 4 (title to follow)	Vincent Danel , Université Grenoble Alpes, France
12:30 – 13:30	Lunch	
13:30 – 14:00	Authors with Posters and Poster Round	

Platinum Room, Friday 25 May 2018 (afternoon)		
Inter-individual Variability Symposium - continued		
Time	Title	Lecturer
Session chair: to be advised		
14:00 – 14:20	Amphetamine and NPS-related toxicity: can pharmacogenomics alter presentation?	Matthias Liechi , University Hospital Basel, Switzerland
14:20 – 14:40	Susceptibility to acetaminophen-induced liver toxicity: the role of liver metabolism	James Dear , University of Edinburgh, UK
14:40 – 15:00	Hypersusceptibility to drugs: why some people are poisoned	Robin Ferner , University of Birmingham, UK
<p><i>At the end of this session the audience should be able to:</i></p> <ul style="list-style-type: none"> • <i>assess which pharmacogenetic characteristics likely influence the clinical effects of amphetamine-type stimulants</i> • <i>explain the contribution of individual variation in liver toxicity after acetaminophen overdose</i> • <i>explain the wide variation in responses to drugs within and between individuals and some of the factors that influence susceptibility to harm from drugs</i> 		
15:00 – 15:45	Coffee and Authors with Posters	

Arizona & Colorado Room, Friday 25 May 2018 (afternoon)		
Paediatric Toxicology Symposium		
Time	Title	Lecturer
Session chair: to be advised		
14:00 – 14:20	Unintentional poisonings due to chemicals in children. Spanish Toxicosurveillance Program	Lidia Martinez , Hospital Sant Joan de Déu, Barcelona, Spain
14:20 – 14:40	The poison centre perspective on unintentional paediatric poisoning	Maren Hermanns-Clausen , Faculty of Medicine, University of Freiburg, Germany
14:40 – 15:00	Binge drinking and chemical submission: impact on teenagers	Régis Bédry , Bordeaux University Hospital, France
<p><i>At the end of this session the audience should be able to:</i></p> <ul style="list-style-type: none"> • <i>describe the main features of the unintentional poisonings due to chemicals in children and explain the importance of detecting risk factors and applying preventive measures</i> • <i>describe circumstances of severe acute unintentional poisoning and related risk factors among children and teenagers</i> • <i>describe factors which explain the behavior of teenagers in relation to binge drinking and which factors make an individual a potential victim to a potential aggressor</i> 		
15:00 – 15:45	Coffee and Authors with Posters	

Platinum Room, Friday 25 May 2018 (afternoon)		
Oral Platform/Short Oral Presentations and Special Presentation		
Time	Title	Lecturer
Session chair: to be advised		
15:45 – 16:00	SEROTONIN TOXICITY: A REGRESSION ANALYSIS OF FREQUENCY AND OUTCOMES (abstract no. 210)	Joyce Cooper , University of Newcastle, Callaghan, Australia
16:00 – 16:05	LARGE INTER-BATCH VARIATION IN ACUTE ADVERSE REACTIONS TO INDIAN POLYVALENT ANTIVENOM (abstract no. 211)	Anjana Silva , Rajarata University of Sri Lanka, Anuradhapura, Sri Lanka
16:05 – 16:10	PRE-WORKOUT SUPPLEMENTS: THE NEW TREND (abstract no. 212)	Chantal Roelen , University Medical Center Utrecht, Utrecht University, The Netherlands
16:10 – 16:30	Preparation and Presentation of ePosters at Scientific Conferences	Ana Ferrer Dufol , Clinical University Hospital, Zaragoza, Spain

Arizona & Colorado Room, Friday 25 May 2018 (afternoon)		
Paediatric Toxicology Symposium - continued		
Time	Title	Lecturer
Session chair: to be advised		
15:45 – 16:05	Safety Profile of Cough and Cold Medication Use in Pediatrics	Jody Green , Inflexion, Boston, USA
16:05 – 16:25	Desferrioxamine: Does it Really Work?	Milton Tenenbein , University of Manitoba, Winnipeg, Canada
16:25 – 16:30	General Discussion	
<p><i>At the end of this lecture the audience should be able to:</i></p> <ul style="list-style-type: none"> • <i>discuss the rate of safety events and common adverse events associated with the use of cough and cold medications in children</i> • <i>discuss the efficacy of desferrioxamine in the management of iron overdose</i> 		

POSTERS

Wednesday 23 May 2018

Drugs of Abuse

29

CLINICAL EFFECTS FOLLOWING 2C-B EXPOSURE: A CASE SERIES OF 20 PATIENTS

30

ACUTE TOXICITY FOLLOWING ANALYTICALLY CONFIRMED USE OF THE NOVEL PSYCHOACTIVE SUBSTANCE (NPS) METHIOPROPAMINE: A REPORT FROM THE IDENTIFICATION OF NOVEL PSYCHOACTIVE SUBSTANCES (IONA) STUDY

31

AN ANALYTICALLY CONFIRMED NON-FATAL INTOXICATION BY THE ULTRA-POTENT FENTANYL ANALOGUE CARFENTANIL IN SWEDEN

32

HIGH WILLINGNESS TO USE RAPID FENTANYL TEST STRIPS AMONG DRUG-USING YOUNG ADULTS

33

NEW PSYCHOACTIVE SUBSTANCE (NPS)-INDUCED TOXICITY REQUIRING INTENSIVE CARE UNIT ADMISSION: A CASE SERIES

34

ANALYTICAL PREVALENCE OF DRUGS OF MISUSE IN HOMELESS PEOPLE PRESENTING WITH SEVERE TOXICITY AFTER SUSPECTED USE OF NOVEL PSYCHOACTIVE SUBSTANCES

35

NOVEL PSYCHOACTIVE SUBSTANCES (NPS) AND EMERGENCY ROOMS (ER): A COMPLICATED RELATIONSHIP?

*36

4-FLUOROMETHYLPHENIDATE (4F-MPH) ABUSE: AN ANALYTICALLY-CONFIRMED CASE

37

DIFFUSE ST ELEVATION ON ELECTROCARDIOGRAM (ECG) CONSISTENT WITH PERICARDITIS SECONDARY TO SMOKING "K2"

38

ACUTE INTRACEREBRAL HAEMORRHAGE FOLLOWING THE USE OF SYNTHETIC CANNABINOIDS AND CATHINONES

39

ACUTE CANNABIS PRESENTATIONS: CLINICAL CHARACTERISTICS AND THE EFFECT OF ETHANOL CO-INGESTION

40

ACUTE DYSKINETIC SYNDROME IN SEVERE AMPHETAMINE POISONING

41

FATALITIES RELATED TO DEXTROMETHORPHAN ABUSE

*Included in poster round 13.30 to 14:00 hrs

42

GABAPENTIN AND THE POTENTIATION OF OPIOID EFFECTS: TWO CASES

43

SATURDAY NIGHT ABSCESS: A BRACHIAL PLEXUS ABSCESS IN AN INTRAVENOUS DRUG USER

44

ANALYTICALLY CONFIRMED RECREATIONAL USE OF OBERACETAM (NOOPEPT®) IN THE UK

45

CLINICAL EFFECTS AND ANALYTICAL IMPLICATIONS OF THE USE OF SCELETIUM TORTUOSUM AND CANNABIS: A CASE REPORT

46

CANNABIS-INDUCED ANAPHYLAXIS

48

INTRAVENOUS INJECTION OF TROPICAMIDE EYE DROPS: THE FIRST CASE REPORTED IN FRANCE

49

CEREBROVASCULAR ULTRASOUND CHANGES IN OPIUM ADDICTED AND NON-ADDICTED ISCHEMIC STROKE PATIENTS

50

LOW GLASGOW COMA SCALE (GCS) DUE TO GAMMAHYDROXYBUTYRATE (GHB) INTOXICATION IS NOT AN INDICATION FOR INTUBATION

51

ILLEGAL DRUG OVERDOSES IN LJUBLJANA, SLOVENIA

52

HYPERTHERMIA IN SYMPATHOMIMETIC/SEROTONERGIC SUBSTANCE OF ABUSE POISONING: A CASE SERIES

53

ACUTE HEALTH PROBLEMS DUE TO RECREATIONAL DRUG USE IN PATIENTS PRESENTING TO AN URBAN EMERGENCY DEPARTMENT IN SWITZERLAND

*54

ONE-YEAR EXPERIENCE WITH THE PARIS SUPERVISED INJECTION SITE: DRUGS USED AND SAFETY ANALYSIS

55

PRESENTATIONS TO THE EMERGENCY DEPARTMENT WITH MISUSE OF BENZODIAZEPINES AND Z-DRUGS: PROFILING AND RELATION TO SALES DATA.

56

DOCTORS' AWARENESS AND PERCEPTION OF PRESCRIPTION MEDICINE MISUSE IN SINGAPORE

57

INTENTIONAL OPIOID EXPOSURES WITH BENZODIAZEPINE COINGESTANTS IN THE US AND EUROPE AS REPORTED TO THE RADARS® SYSTEM GLOBAL TOXICOSURVEILLANCE NETWORK

*Included in poster round 13.30 to 14:00 hrs

Novel Oral Anticoagulants

*58

A NINE YEAR RETROSPECTIVE REVIEW OF TRENDS IN ORAL ANTICOAGULANT ENQUIRIES TO THE UK NATIONAL POISONS INFORMATION SERVICE

59

PREVENTION OF DIRECT ORAL ANTICOAGULANT PRESCRIPTION ERRORS USING OBLIGATORY PREREQUISITE REVIEW BY CLINICAL PHARMACISTS

60

IDARUCIZUMAB IN A CLINICAL TOXICOLOGY SETTING: THE ITALIAN EXPERIENCE

61

REVERSIBLE DABIGATRAN-INDUCED NEUTROPENIA AFTER A SINGLE DOSE

62

ERRONEOUS ADMINISTRATION OF THE DABIGATRAN ANTIDOTE IDARUCIZUMAB DURING SURGERY: CASE REPORT AND LESSONS LEARNED

63

APIXABAN AND RIVAROXABAN INGESTION IN CATS AND DOGS

Animal and Veterinary Toxicology

64

DIGITALIS SPECIES (FOXGLOVE) INGESTION IN 47 DOMESTIC GUINEA PIGS (CAVIA PORCELLUS)

65

FERRIC PHOSPHATE MOLLUSCICIDE EXPOSURE IN DOGS: LOW RISK OF POISONING

66

EXPOSURE TO ORNITHOGALUM PLANTS: A CAUSE OF BLINDNESS IN SMALL ANIMALS?

67

NON-ACCIDENTAL POISONING OF DOMESTIC AND WILD ANIMALS IN FERRARA PROVINCE, ITALY

68

SUCCESSFUL MANAGEMENT OF ACUTE KIDNEY FAILURE IN DOG FOLLOWING CALCIPOTRIOL INGESTION

69

5-FLUOROURACIL INGESTION IN DOGS

70

CLITOCYBE RIVULOSA POISONING IN DOGS

71

INCREASED AMYLASE AND LIPASE ACTIVITY AFTER MUSHROOM INGESTION IN DOGS

Occupational Toxicology

72

BACK-CALCULATION OF THE PEAK PLASMA CONCENTRATION AND PROTEOMICS FINDING 50 YEARS FOLLOWING 2,3,7,8-TETRACHLORO-DIBENZO-P-DIOXIN EXPOSURE

*Included in poster round 13.30 to 14:00 hrs

73

DIFFUSE ALVEOLAR DAMAGE (CHEMICAL PNEUMONITIS) AFTER INHALATION OF NITROGEN OXIDES FUMES BY AN ELECTROPLATING WORKER

74

PERACETIC ACID EXPOSURES REPORTED TO THE DUTCH POISONS INFORMATION CENTER

*75

COMPARISON OF OCCUPATIONAL POISONING CASES REPORTED TO THE GERMAN BFR AND ENQUIRIES IN THE POISONS CENTRES IN GERMANY

76

OCCUPATIONAL LEAD EXPOSURE AND MULTIPLE ORGAN DYSFUNCTION: A CASE SERIES

Poisons Centre Activities

77

THE IMPACT OF WWW.POISONCENTRE.BE AND SOCIAL MEDIA ON THE NUMBER AND CHARACTERISTICS OF CALLS TO THE BELGIAN POISON CENTRE

78

AGOMELATINE-RELATED TOXICITY REPORTED TO THE VICTORIAN POISONS INFORMATION CENTRE

79

BEING PARACELTUS: THE TOXICOLOGY EDUCATIONAL CARD GAME

80

INADVERTENT INSTILLATION OF ELECTRONIC CIGARETTE LIQUID AS EYE DROPS

81

INHALANT ABUSE IN NEW ZEALAND: ARE THE WARNINGS BEING TAKEN IN?

82

BACLOFEN EXPOSURES REPORTED TO THE UK NATIONAL POISONS INFORMATION SERVICE (NPIS) OVER 12 YEARS (2005-2017)

83

A REVIEW OF THE METHODS AND EFFICIENCY OF FOLLOW-UP OF ENQUIRIES TO THE UK NATIONAL POISONS INFORMATION SERVICE (NPIS) IN 2016

84

WONDER CHEMISTRY: EXPOSURES RELATED TO CHEMISTRY SETS, 2008-2017

85

SPECIALIST IN POISON INFORMATION (SPI)-INITIATED TOXICOLOGY CONSULTS: TRENDS FROM A REGIONAL POISON CENTER

86

DANGEROUS EXPERIMENTS WITH THE DRUGS AGAINST DRY COUGH

87

THE ROLE OF THE UK NATIONAL POISONS INFORMATION SERVICE (NPIS) IN THE DIAGNOSIS OF DEATH IN POISONED AND NON-POISONED PATIENTS

*Included in poster round 13.30 to 14:00 hrs

88

USER EXPERIENCE OF THE TOXBASE APP

89

COMPARISON OF LIQUID LAUNDRY DETERGENT PODS AND OTHER LAUNDRY DETERGENT EXPOSURES IN CHILDREN: AN 11 MONTH SURVEY IN AUSTRIA

90

RESULTS FROM THE EU LIQUICAPS STUDY: A COMPARISON BETWEEN CASES OF POISONING AGED <5 YEARS AND EXPOSED TO LAUNDRY DETERGENTS

91

EU LIQUICAPS STUDY: AN EVALUATION OF IMPACT OF REGULATION (EU) NO 1297/2014 ON FREQUENCY OF EXPOSURE TO LIQUID LAUNDRY DETERGENT CAPSULES AND POISONING SEVERITY

92

USE AND SAFETY OF MOOD STABILIZERS AND ANTIPSYCHOTIC DRUGS DURING PREGNANCY: THE EXPERIENCE OF THE FLORENCE TERATOLOGY INFORMATION SERVICE

93

PETROLEUM DISTILLATE POISONING IN THE UK: THE NATIONAL POISONS INFORMATION SERVICE (NPIS) EXPERIENCE

94

POISONING IN THE ELDERLY: CHARACTERIZATION OF EXPOSURES REPORTED TO THE DUTCH POISONS INFORMATION CENTER

95

CARBON MONOXIDE POISONING: DATA FROM THE UK NATIONAL POISONS INFORMATION SERVICE (NPIS)

*96

ORAL METHOTREXATE EXPOSURE: A 15-YEAR SURVEY OF AUSTRIAN POISONS INFORMATION CENTRE CASES

Heavy Metal Poisoning

97

MASSIVE LEAD POISONING FROM A GUNSHOT WITH HIGH SOFT LEAD CHARGE

98

METAL RELEASE FROM SPINAL ARTHRODESIS: TWO CASES WITH TITANIUM-ALLOY IMPLANT FAILURE AND LOCAL METAL RELEASE BUT MILD ELEVATION OF SERUM CONCENTRATIONS

99

BIOCHEMICAL EFFECTS OF LEAD IN EXPOSED WORKERS WITH RESPECT TO LIVER AND KIDNEY FUNCTION TESTS

100

A NATIONAL SURVEY OF THE LEVEL OF KNOWLEDGE OF ORTHOPEDIC SURGERY RESIDENTS REGARDING SYSTEMIC COBALT TOXICITY ASSOCIATED WITH TOTAL HIP ARTHROPLASTY

101

MERCURY EXPOSURES FROM MEASURING DEVICES REPORTED TO THE UK NATIONAL POISONS INFORMATION SERVICE, 2008–2016

*Included in poster round 13.30 to 14:00 hrs

102

OCCUPATIONAL LEAD POISONING – SIMILARITIES AND DIFFERENCES: TWO CASE REPORTS

103

SEVERE SYMPTOMS FOLLOWING “HEAVY METAL DETOXIFICATION”

104

INTRACORPOREAL BULLETS: SCREENING FOR LEAD POISONING AND SETTING UP OF A MEDICAL FOLLOW-UP

Toxinology

105

CHARACTERIZATION OF SPIDER BITES IN CHILDREN: REPORT OF THE MOROCCAN POISON CONTROL CENTRE (2000–2012)

106

HOW OFTEN DO SNAKEBITE PATIENTS RECEIVE PROPHYLACTIC STEROIDS OR ANTIHISTAMINES BEFORE FAB ANTIVENOM?

107

A MISUSE OF SNAKEBITE ANTIDOTE MAY BE LIFE-THREATENING FOR PATIENTS: A FRENCH CASE OF EUROPEAN VIPERA SPECIES ENVENOMATION TREATED WITH VIPERATAB®

108

ADDER BITES IN FINLAND: DEMOGRAPHIC DATA FROM POISON CENTRE ENQUIRIES

109

SPIDERS BITES IN ITALY: DATA COLLECTION OF A POISON CONTROL CENTER

110

WAVE BIOMECHANOTHERAPY FOR THE REHABILITATION OF PATIENTS BITTEN BY VIPERA BERUS

111

ASYMPTOMATIC PULMONARY HEMORRHAGE ON CHEST COMPUTED TOMOGRAPHY (CT) AFTER BOTHROPS SPP SNAKEBITE

112

NAJA MOSSAMBICA SNAKEBITE IN KENTUCKY

113

MICROANGIOPATHIC HEMOLYTIC ANEMIA AND ACUTE KIDNEY INJURY FOLLOWING BOTHROPS JARARACA SNAKEBITE

114

IS ANTIVENOM TREATMENT FOR NAJA KAOUTHIA BITES ALWAYS NECESSARY IN HIGH CARE HOSPITALS?

POSTERS

Thursday 24 May 2018

Mechanisms of Toxicity and Basic Research

127

WHAT ARE THE EXACT MECHANISMS INVOLVED IN TRAMADOL-INDUCED SEIZURES IN OVERDOSE? AN EXPERIMENTAL INVESTIGATION IN THE RAT

*128

INVESTIGATION OF INTRAVENOUS LIPID EMULSION ON QUETIAPINE PHARMACOKINETICS IN THE RAT: IS THE LIPID SINK THEORY VALID?

129

THE EFFECTS OF CANNABINOIDS ON ASTROCYTIC VIABILITY AND NEUROTROPHIC ACTIVITY

130

MECHANISMS OF TOXICITY INVOLVED IN METAMIZOLE-ASSOCIATED NEUTROPENIA

131

MITOCHONDRIAL TOXICITY AND OXIDATIVE STRESS INDUCED BY METHYLENE BLUE AND TOLUIDINE BLUE IN MAMMALIAN CELLS

132

NEUROTOXICITY OF CATHINONES: EFFECTS ON IN VITRO NEURONAL ACTIVITY

*133

INVESTIGATION OF THE NEURO-RESPIRATORY EFFECTS OF BUPRENORPHINE/ETHANOL COMBINATION IN THE RAT: EVIDENCE FOR A PHARMACODYNAMIC DRUG-DRUG INTERACTION

134

ADVANCED ELECTROCARDIOGRAM (ECG) ANALYSIS IN THE AMITRIPTYLINE-POISONED PIG TREATED WITH COATED ACTIVATED CHARCOAL HEMOPERFUSION (CAC-HP)

135

AMITRIPTYLINE ACCUMULATION IN TISSUES AFTER COATED ACTIVATED CHARCOAL HEMOPERFUSION: A RANDOMIZED CONTROLLED ANIMAL POISONING MODEL

136

EVALUATION OF THE HEPATOPROTECTIVE FUNCTIONS OF SCHIZOPHILLUM COMMUNE IN MICE WITH EXPERIMENTAL HEPATITIS CAUSED BY CARBON TETRACHLORIDE

*137

EFFECT FINGERPRINTING OF CATHINONES: LESSONS FROM IN VITRO DATA

138

EFFECTS OF ACTIVE AND PASSIVE SMOKING ON SERUM OXIDATIVE STRESS BIOMARKERS IN PSYCHIATRIC PATIENTS

139

BIOMARKERS OF ENDOTHELIAL DYSFUNCTION IN ACUTE COCAINE DRUG OVERDOSE

*Included in poster round 13.30 to 14:00 hrs

Epidemiology and Toxicsurveillance

140

PHARMACOVIGILANCE: A 4-YEAR POISONS INFORMATION CENTER PILOT SURVEY OF ATYPICAL ANTIPSYCHOTICS

141

UNEXPECTED TOXICITY OF CANNABIDIOL (CBD) OIL HEALTH PRODUCTS

142

THIRTY YEARS OF INPATIENT TOXICOLOGY DEATHS

143

CORONERS' REPORTS TO PREVENT FUTURE DEATHS RELATED TO POISONING IN ENGLAND AND WALES: RELEVANCE TO TOXICOSURVEILLANCE

144

ORAL ALKALINE PH DROPS: RISK OF CHEMICAL INJURIES

145

THE EPIDEMIOLOGY AND SEVERITY OF SCORPION ENVENOMING IN SOUTH AFRICA: DATA FROM THE TYGERBERG POISONS INFORMATION CENTRE OVER A 10 YEAR PERIOD

146

HUMAN H1-ANTIHISTAMINE EXPOSURES REPORTED TO THE POISONS INFORMATION CENTRE ERFURT FROM 2007 TO 2016

147

POISONING IN THE UK: WHAT IS THE TRUE INCIDENCE?

148

EPIDEMIOLOGY OF ACUTE METFORMIN POISONING IN CHILDREN: A 5 YEAR STUDY

149

EPIDEMIOLOGY OF INTENTIONAL POISONING IN CHILDREN ADMITTED TO A TOXICOLOGY DEPARTMENT

150

MEDICATION POISONING IN CHILDREN: MOROCCAN POISON CONTROL AND PHARMACOVIGILANCE CENTRE DATA

151

RACIAL AND ETHNIC CHARACTERISTICS IN CASES OF INTENTIONAL PHARMACEUTICAL EXPOSURE WITH CONCERN FOR TOXICITY

152

CHARACTERISTICS OF EMERGENCY POISONING CASES DURING FESTIVAL OF SAN FERMIN. WHAT HAPPENS IN PAMPLONA?

*153

POISONING WITH BENZODIAZEPINES AS WELL AS PSYCHIATRIC COMORBIDITY MAY INDICATE AN INCREASED RISK FOR REPEATED POISONING

*Included in poster round 13.30 to 14:00 hrs

154
EPIDEMIOLOGY OF ACUTE POISONING IN UGANDA: AN 8-YEAR ANALYSIS

155
USAGE OF EXTRACORPOREAL TREATMENT IN HUNGARY

Management of the Poisoned Patient

156
THE NACSTOP TRIAL: A MULTI-CENTRE, CLUSTER, CONTROLLED TRIAL INVESTIGATING THE EARLY CESSATION OF N-ACETYLCYSTEINE IN PARACETAMOL OVERDOSE

157
ACUTE LIVER FAILURE OF UNCLEAR CAUSE? PARACETAMOL ADDUCTS MAKE THE DIAGNOSIS

*158
UNINTENTIONAL PARACETAMOL OVERDOSE: 3-YEAR ANALYSIS OF PATIENTS ADMITTED FOR TREATMENT WITH ACETYLCYSTEINE TO A TOXICOLOGY UNIT IN THE UK

159
DELAYED ABSORPTION OF PARACETAMOL DUE TO COINGESTION OF A BEZOAR-FORMING PHARMACEUTICAL

160
PARACETAMOL OVERDOSE IN PREGNANCY: A CASE REPORT

161
FEWER ADVERSE DRUG REACTIONS TO ACETYLCYSTEINE IN PARACETAMOL OVERDOSE USING A REDUCED BOLUS 2-BAG PROTOCOL COMPARED TO THE TRADITIONAL 3-BAG PROTOCOL: A META-ANALYSIS

162
NON-ANION GAP ACIDOSIS IN SIGNIFICANT SALICYLATE POISONING: MIND THE NON-GAP!

163
POISONINGS WITH TWO NEW ANTIEPILEPTIC DRUGS: LACOSAMIDE AND PERAMPANEL

164
SEIZURE AFTER MASSIVE GABAPENTIN OVERDOSE

165
A PHARMACOKINETIC ANALYSIS OF HEMODIALYSIS FOR METFORMIN-ASSOCIATED LACTIC ACIDOSIS

166
ESTIMATION OF THE DIALYSIS TIME FOR PATIENT WITH EXTREMELY HIGH ETHYLENE GLYCOL LEVEL

167
EPIDEMIOLOGY OF ORGAN FAILURE IN POISONED PATIENTS: A 16-YEAR EXPERIENCE OF AN ITALIAN INTENSIVE CARE UNIT

168
CLINICAL FEATURES AND PHARMACOKINETIC ANALYSIS IN ACUTE OLANZAPINE POISONING IN PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT

*Included in poster round 13.30 to 14:00 hrs

- 170
PROLONGED ELIMINATION AFTER MASSIVE OVERDOSE OF METOPROLOL AND AMLODIPINE IN A PATIENT TREATED WITH EXTRACORPOREAL LIFE SUPPORT (ECLS)
- 171
ARE THE NEW-GENERATION ANTICONVULSIVE DRUGS RESPONSIBLE FOR SEVERE TOXICITY? AN INTENSIVE CARE UNIT CASE SERIES WITH PHARMACOKINETIC DATA
- 172
ACUTE AMITRIPTYLINE AND CLOMIPRAMINE POISONING IN THE INTENSIVE CARE UNIT: CLINICAL PRESENTATION AND PHARMACOKINETIC MODELLING
- 173
CARDIAC ARREST FOLLOWING SEVERE AUTOINTOXICATION WITH CHLOROQUINE
- 174
KINETICS OF HYDOXYCHLOROQUINE FOLLOWING MASSIVE OVERDOSE
- 175
INTENTIONAL INJECTION WITH HIGH DOSE INSULIN DEGLUDEC RESULTING IN PROLONGED HOSPITALIZATION AND SUSPECTED INSULIN OEDEMA
- 176
INSULIN OVERDOSE: A SYSTEMATIC REVIEW OF CASE REPORTS WITH FOCUS ON CLINICAL COURSE, COMPLICATIONS AND EXPERIMENTAL TREATMENT OPTION
- 177
REFRACTORY BRADYCARDIA AND HEART RATE-DEPENDENT HYPOTENSION FOLLOWING VERAPAMIL AND TELMISARTAN OVERDOSE RESPONDING TO EMERGENCY TRANSVENOUS CARDIAC PACING
- 178
LEVOSIMENDAN AS A POTENTIAL CALCIUM CHANNEL BLOCKER ANTIDOTE: A SYSTEMATIC LITERATURE REVIEW
- 179
CHRONIC DIGITALIS POISONING TREATED WITH ANTI-DIGOXIN FAB FRAGMENTS: A CRITICAL ANALYSIS OF TREATMENT INDICATIONS AND PATIENT OUTCOME
- 180
DELAYED QTC PROLONGATION AFTER SUPRATHERAPEUTIC LOPERAMIDE USE TO TREAT CHRONIC DIARRHEA ASSOCIATED WITH IRRITABLE BOWEL SYNDROME
- 181
COLCHICINE POISONING PRESENTING WITH ACUTE MYOCARDIAL INFARCTION AND SECONDARY CARDIOGENIC SHOCK
- 182
SEVERE CARDIOVASCULAR FAILURE IN RELATION TO BETA-BLOCKER POISONING: PREDICTIVE FACTORS, PHARMACOKINETICS AND EFFECT/CONCENTRATION RELATIONSHIPS
- 183
CARBON MONOXIDE POISONING IN PRE-HOSPITAL AND EMERGENCY DEPARTMENT HOSPITAL SETTINGS: CRITICAL ISSUES ON CORRECT EVALUATION AND PROPOSAL OF A CLINICAL PROCEDURE
- 184
CARBON MONOXIDE EXPOSURES AND HYPERBARIC OXYGEN THERAPY: A REVIEW OF THE TOXIC REGISTRY

- 185
LISDEXAMFETAMINE OVERDOSE IN ADOLESCENTS AND ADULTS: EXPERIENCE IN SWEDEN
- 186
DULOXETINE OVERDOSE
- 187
DELAYED RESOLUTION OF AMITRIPTYLINE TOXICITY ASSOCIATED WITH CYP2D6 DEFICIENCY
- 188
SEVERE CENTRAL NERVOUS SYSTEM DEPRESSION AND ACUTE RESPIRATORY DISTRESS SYNDROME IN SEVERE NISOLDIPINE TOXICITY
- 189
USING PESTICIDE-POISONED PATIENTS AS POTENTIAL ORGAN DONORS
- 190
PREDICTING OUTCOMES IN ALUMINUM PHOSPHIDE POISONING USING A RISK-PREDICTION NOMOGRAM
- 191
SEVERE SUICIDAL SELF-POISONING WITH MASSIVE DOSE OF POTASSIUM FERRICYANIDE: RISK OF LIFE-THREATENING HYPERKALEMIA AND ACUTE RENAL FAILURE
- 192
LACTATION IN BETA-THALASSEMIA MAJOR: IS DEFERASIROX COMPATIBLE? THE FIRST CASE WITH CLINICAL DATA AND BREASTMILK CONCENTRATIONS
- 193
LIQUID BROMINE INGESTION: A RARE ENTITY
- 194
A PATIENT WITH DIMETHOATE POISONING REQUIRING PROLONGED DECONTAMINATION
- 195
A CASE OF COPPER ACETOARSENITE POISONING
- 196
HYDROXOSAVE: EMPIRIC PREHOSPITAL CYANIDE TREATMENT WITH HYDROXOCOBALAMIN IN HOUSE FIRE PATIENT
- 197
DERMAL EXPOSURE TO HYDROFLUORIC AND SULFURIC ACID TREATED WITH YOGURT
- 198
HEALTHCARE PROFESSIONALS' EXPERIENCE IN HAZMAT PREPAREDNESS AND RESPONSES IN THAILAND
- 199
EXTRAORDINARY MOBILIZATIONS OF BOTULINUM-ANTI-TOXIN FROM THE NATIONAL STOCKPILE TO THE EMERGENCY DEPARTMENT: AN EFFICIENT AND VERSATILE SYSTEM FOR THE PROVISION OF EMERGENCY
- 200
HALLUCINATIONS AND SEIZURES: WHAT ARE THE MOST LIKELY CAUSES?
- 201
FREQUENCY AND BURDEN OF DELIRIUM IN DRUG OVERDOSE PATIENTS

202

DEFINITION AND TREATMENT OF BENZODIAZEPINE-RESISTANT ETHANOL WITHDRAWAL SYNDROME

203

PRACTICE VARIATION IN THE INITIAL TREATMENT OF PATIENTS WITH ETHANOL WITHDRAWAL SYNDROME (EWS)

204

AN OUTBREAK OF FOODBORNE BOTULISM IN ROME, ITALY

205

PROBABLE CASE OF BOTULISM: TREATING WITH A GRAIN OF SALT

POSTERS

Friday 25 May 2018

Paediatric Poisoning

213

A NEW CONCENTRATION OF A PEDIATRIC IBUPROFEN SUSPENSION AVAILABLE FOR PURCHASE: ANALYSIS OF THE IMPACT ON THERAPEUTIC ERRORS

214

ACUTE PEDIATRIC POISONING IN SLOVAKIA: CHANGES OVER THE YEARS.

*215

UNINTENTIONAL PEDIATRIC EXPOSURES TO PRESCRIPTION MEDICATIONS IN EUROPE AS REPORTED TO THE RADARS® SYSTEM GLOBAL TOXICOSURVEILLANCE NETWORK

216

NEONATAL ABSTINENCE FROM MATERNAL KRATOM USE

217

CHOLINERGIC CRISIS IN A TODDLER AFTER ACCIDENTAL PYRIDOSTIGMINE INTOXICATION

218

PRONOUNCED HYPERCHLOREMIC ACIDOSIS AFTER SALT DOUGH INGESTION IN A TODDLER

219

PEDIATRIC VITAMIN D POISONING: A REVIEW OF THE LITERATURE

220

PUT A STOPPER ON THE DROPPER: A CASE OF SEVERE HYPERCALCEMIA WITH BILATERAL MEDULLAR NEPHROCALCINOSIS DUE TO SUPRATHERAPEUTIC VITAMIN D SUPPLEMENTATION

*221

PEDIATRIC VITAMIN D POISONING: DIAGNOSTIC AND TREATMENT ALGORITHM UPDATE

222

CLINICAL AND BIOLOGICAL ISSUES IN ACUTE MUSHROOM POISONING IN CHILDREN: A 3-YEAR RETROSPECTIVE STUDY

223

DANGERS OF PEDIATRIC COMPOUNDING: TOXICITY FROM A COMPOUNDED OMEPRAZOLE SOLUTION

224

SEVERE IRRITATION AFTER COLLODION-BASED WART REMOVER INGESTION IN CHILDREN: A CASE SERIES

225

PEDIATRIC EXTRACORPOREAL CARDIOPULMONARY RESUSCITATION IN THE EMERGENCY ROOM FOR INTENTIONAL PROPAFENONE INTOXICATION

226

ADOLESCENT POISONING IN EDINBURGH: A 10 YEAR ANALYSIS

*Included in poster round 13.30 to 14:00 hrs

227

PUDENDAL BLOCK SUB PARTU MAY INDUCE TRANSIENT NEONATAL METHEMOGLOBINEMIA

228

ELECTROENCEPHALOGRAM (EEG) ALTERATIONS DURING TETRAHYDROCANNABINOL (THC) INGESTION IN CHILDREN: A CASE SERIES

229

PAEDIATRIC EXPOSURES INVOLVING OPIOID MEDICATIONS IN NEW ZEALAND

230

ESCITALOPRAM OVERDOSE IN CHILDREN AND ADOLESCENTS

231

ANALYSIS OF CROATIAN POISON CONTROL CENTRE CONSULTATIONS INVOLVING POISONINGS IN PRESCHOOL CHILDREN (2007-2016) AS A BASIS FOR POISONING PREVENTION ACTION

232

ALPHA LIPOIC ACID POISONING: CASE REPORT

233

EPIDEMIOLOGY OF ACUTE UNINTENTIONAL POISONING IN CHILDREN: A 3-YEAR RETROSPECTIVE STUDY

234

ACUTE BENZODIAZEPINE POISONING IN CHILDREN: A 2-YEAR RETROSPECTIVE STUDY

*235

IS SLIME DANGEROUS? DATA FROM THE FRENCH POISON CENTERS

236

THE ETIOLOGICAL SPECTRUM AND SOCIAL IMPACT ON ADOLESCENTS WITH ACUTE POISONING

237

ACUTE POISONING IN CHILDREN AND ADOLESCENTS IN VOJVODINA, SERBIA

238

EVOLUTION OF THE EPIDEMIOLOGICAL PROFILE OF PAEDIATRIC POISONING IN 20 YEARS AT THE EMERGENCY DEPARTMENT OF A GENERAL HOSPITAL

239

STRONG ALKALI INGESTION IN CHILDREN: A 2-YEAR RETROSPECTIVE STUDY

240

POISONING WITH CHOLINESTERASE-INHIBITING INSECTICIDES: EXPERIENCE FROM TWO PEDIATRIC POISONING CENTRES

241

“BLUE BABY SYNDROME” AND DRINKING WATER

Household Products Poisoning

242

DETERMINATION OF MOTHBALL COMPOSITION IN THE HOME USING CARBONATED SODAS

*Included in poster round 13.30 to 14:00 hrs

243

OCULAR INJURIES FROM HEAD LICE SHAMPOOS CONTAINING A MIXTURE OF MINERAL OIL AND DETERGENTS:
A CONSECUTIVE CASE SERIES

244

ISOPROPYL ALCOHOL OVERDOSE MASQUERADING AS ETHYLENE GLYCOL TOXICITY

245

EYE BURNS DUE TO LIQUID LAUNDRY DETERGENT CAPSULES DISTRIBUTED AS PROMOTIONAL GIFT VIA
MAILSHOT LETTER

246

AVAILABILITY AND STORAGE OF HAZARDOUS PRODUCTS IN HOUSEHOLDS OF THE MANAUS METROPOLITAN
REGION, BRAZIL: POPULATION-BASED SURVEY

247

MANAGING SUPERGLUE EXPOSURE: A STICKY SUBJECT

248

ASPIRATION AND DERMAL LESIONS AFTER DISINFECTANT DETERGENT EXPOSURE IN A TODDLER

249

CEREBELLAR INFARCTION FOLLOWING ACCIDENTAL INHALATION OF TOLUENE-CONTAINING PAINT

250

RISK EVALUATION OF CAUSTIC CHEMICALS USED AS HOUSEHOLD CLEANING PRODUCTS

251

INTOXICATIONS WITH FOOD SUPPLEMENTS: AN UNDERESTIMATED RISK?

Adverse Reactions from Medicines

252

CLOZAPINE INCREASES THE INCIDENCE OF PNEUMONIA COMPARED TO RISPERIDONE AND TO NO
ANTIPSYCHOTIC MEDICATION IN THE GENERAL HOSPITAL POPULATION

253

PEDIATRIC ADVERSE REACTION FROM ELTROMBOPAG: PHARMACOKINETIC AND PHARMACOGENETIC
EVALUATION

254

RENAL DYSFUNCTION IS ASSOCIATED WITH A HIGHER RISK OF CARDIOTOXICITY FOLLOWING ANTI-CANCER
THERAPY AMONG FEMALE PATIENTS WITH EARLY BREAST CANCER

255

HYDROCHLOROTHIAZIDE-INDUCED NON-CARDIOGENIC PULMONARY EDEMA: A SEVERE LIFE-THREATENING
ADVERSE REACTION

256

A HARD STOP: CLOZAPINE WITHDRAWAL CAUSING SEROTONIN SYNDROME

257

FATAL LIVER FAILURE AFTER THERAPEUTIC DOSES OF PARACETAMOL IN A DUCHENNE PATIENT: A CASE REPORT

258

BLACK HAIRY TONGUE (BHT) ASSOCIATED WITH USE OF AMOXICILLIN: THREE CASE REPORTS

259
MULTI-ORGAN FAILURE AND TAKOTSUBO CARDIOMYOPATHY AFTER OFF-LABEL USE OF BACLOFEN FOR TREATMENT OF ALCOHOL ADDICTION: A CASE REPORT

260
DRUG-INDUCED HEPATITIS AFTER EXPOSURE TO NUVARING® (ETONOGESTREL/ETHINYL ESTRADIOL VAGINAL RING) IN A PATIENT WITH GILBERT'S SYNDROME

261
DEXRAZOXANE FOR RAPID EXTENDED LIVEDO RETICULARIS-LIKE SKIN REACTION DUE TO SYSTEMIC EPIRUBICIN DIFFUSION DURING TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) FOR HEPATOCELLULAR CARCINOMA

262
AUDITORY AND VISUAL HALLUCINATIONS AFTER ORAL ADMINISTRATION OF AMOXICILLIN: HOIGNE'S SYNDROME?

263
THE USE OF SUBCUTANEOUS HYALURONIDASE IN THE TREATMENT OF DEXTROSE 50% (D50) SOFT TISSUE EXTRAVASATION

264
ANALYSIS OF THE CASES OF ANAPHYLACTIC AND ANAPHYLACTOID DRUG REACTIONS: A RETROSPECTIVE STUDY

265
CHOREIFORM MOVEMENTS IN A PATIENT AFTER ROUTINE BILATERAL SACROILIAC JOINT INJECTIONS WITH LIDOCAINE

266
MITOMYCIN C ADVERSE REACTION AFTER INTRAVESICAL INSTILLATION

267
INTRAVENOUS IRON OVERDOSE: TREAT THE PATIENT NOT THE NUMBER

Plant and Mushroom Poisoning

268
PREVENTION OF MUSHROOM POISONINGS IN POPULATION OF FOREIGN ORIGIN IN NORWAY

269
MUSHROOM POISONING IN FINLAND: REVIEW OF ENQUIRIES RECEIVED BY THE FINNISH POISON INFORMATION CENTRE (FPIC) IN 2014-2016

270
HIGH-DOSE MAGNESIUM SULPHATE IN THE TREATMENT OF ACONITE DYSRHYTHMIA

271
NEUROLOGICAL SYMPTOMS AFTER CONSUMPTION OF EARTHBALLS (SCLERODERMA SPECIES): A RETROSPECTIVE CASE SERIES

272
KRATOM: NATURAL PAINKILLER OR HERBAL ENEMY?

273
ANALYTICALLY CONFIRMED ACONITINE POISONING AS A RESULT OF MISTAKING MONKSHOOD LEAVES FOR LOVAGE

*274

ACCIDENTAL INGESTION OF OUTDOOR MUSHROOMS IN CHILDREN: A 1-YEAR SURVEY OF THE AUSTRIAN POISONS INFORMATION CENTRE

275

POISONOUS SMOOTHIE: ACUTE GASTROENTERITIS FROM CRUSHED CHERIMOYA SEEDS

276

TAXUS BACCATA (YEW) INTOXICATION TREATED WITH SODIUM BICARBONATE AND LIPID EMULSION

277

FOOD-BORNE BOTULISM, INITIALLY MISTAKEN FOR PLANT INTOXICATION

278

A UNIQUE CASE REPORT OF A FAMILY EXPOSED TO AMATOXIN FROM FORAGED MUSHROOMS INCLUDING A BREAST-FEEDING MOTHER AND INFANT

279

AMANITA PHALLOIDES POISONING: EFFECTIVENESS OF TIMELY ADMINISTRATION OF ANTIDOTES

*280

CYANOGENIC GLYCOSIDE INGESTIONS: A REVIEW OF ENQUIRIES RECEIVED BY THE UK NATIONAL POISONS INFORMATION SERVICE (NPIS), 2008-2016

281

ACUTE HEPATITIS FOLLOWING VALERIAN ROOT INGESTION

282

NEUROTOXIC SHELLFISH POISONING FROM THE CONSUMPTION OF CONTAMINATED CONCH

283

A NEW CASE OF FLAGELLATE DERMATITIS AFTER INGESTION OF SHIITAKE MUSHROOMS WITH GENERAL SYMPTOMS AND PUSTULOSIS

284

AMATOXIN POISONING: A 30-YEAR RETROSPECTIVE ANALYSIS AND EVALUATION OF 153 PATIENTS

285

A SIGNIFICANT PORTION OF MODERATE TO SEVERE COURSES AFTER INGESTION OF MUSHROOMS IS CAUSED BY INADEQUATELY STORED OR PREPARED EDIBLE MUSHROOMS

286

REGIONAL ILEITIS AS A NON-SPECIFIC SYMPTOM OF BOLETUS SPECIES POISONING

287

ACCIDENTAL FATAL POISONING WITH COLCHICUM AUTUMNALE DUE TO MISTAKEN IDENTIFICATION: A CASE REPORT

288

A RETROSPECTIVE INVESTIGATION OF THE IMPACTS OF ALIEN AND NATIVE PLANT TAXA ON HUMAN HEALTH: A CASE STUDY OF TWO POISON INFORMATION CENTERS

*Included in poster round 13.30 to 14:00 hrs

289

RHABDOMYOLYSIS ASSOCIATED WITH MUSHROOM POISONING: CLINICAL CHARACTERISTICS AND
OUTCOMES